NO20072601L - Azaindolkarboksamider - Google Patents
AzaindolkarboksamiderInfo
- Publication number
- NO20072601L NO20072601L NO20072601A NO20072601A NO20072601L NO 20072601 L NO20072601 L NO 20072601L NO 20072601 A NO20072601 A NO 20072601A NO 20072601 A NO20072601 A NO 20072601A NO 20072601 L NO20072601 L NO 20072601L
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- azaindolkarboksamider
- ht1a
- compounds
- treatment
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000008054 signal transmission Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004054634A DE102004054634A1 (de) | 2004-11-12 | 2004-11-12 | Azaindolcarboxamide |
| PCT/EP2005/012127 WO2006050976A1 (fr) | 2004-11-12 | 2005-11-11 | Carboxamides d'azaindole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072601L true NO20072601L (no) | 2007-05-22 |
Family
ID=35929547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072601A NO20072601L (no) | 2004-11-12 | 2007-05-22 | Azaindolkarboksamider |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070299091A1 (fr) |
| EP (1) | EP1771448A1 (fr) |
| JP (1) | JP2008519797A (fr) |
| KR (1) | KR20070083843A (fr) |
| CN (1) | CN101056878A (fr) |
| AU (1) | AU2005303904A1 (fr) |
| BR (1) | BRPI0517846A (fr) |
| CA (1) | CA2575668A1 (fr) |
| DE (1) | DE102004054634A1 (fr) |
| EA (1) | EA200700909A1 (fr) |
| IL (1) | IL180317A0 (fr) |
| MX (1) | MX2007005649A (fr) |
| NO (1) | NO20072601L (fr) |
| WO (1) | WO2006050976A1 (fr) |
| ZA (1) | ZA200700252B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| ES2239196T3 (es) | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
| EP1547592A1 (fr) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Formulation intranasale contenant |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| CA2690789C (fr) | 2007-06-15 | 2014-08-05 | Amy Hauck Newman | Derives de la 4-phenylpiperazine avec des lieurs fonctionnalises tels que les ligands selectifs du recepteur d<sb>3</sb> de la dopamine et procedes d'utilisation |
| AU2010339444A1 (en) | 2009-12-30 | 2012-07-19 | Arqule, Inc. | Substituted pyrrolo-aminopyrimidine compounds |
| EP2867236B1 (fr) | 2012-06-29 | 2017-06-14 | Pfizer Inc | Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2 |
| BR112015019276A2 (pt) * | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| EP3083618B1 (fr) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2 |
| WO2016012896A1 (fr) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Composés de pyrazolopyrimidine |
| MD20170011A2 (ro) | 2014-08-06 | 2017-08-31 | Pfizer Inc. | Compuşi imidazopiridazinici |
| AU2016301188A1 (en) | 2015-08-06 | 2018-02-15 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| US11299476B2 (en) | 2016-03-14 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof |
| SI3429993T1 (sl) | 2016-03-14 | 2021-09-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer | Selektivni antagonisti/delni agonisti dopaminskega receptorja D3; postopki izdelave; in uporaba le-teh |
| WO2018021447A1 (fr) | 2016-07-28 | 2018-02-01 | 塩野義製薬株式会社 | Composé cyclique condensé contenant de l'azote ayant un effet antagoniste du récepteur de la dopamine d3 |
| CN106279071B (zh) * | 2016-08-10 | 2019-01-04 | 广东东阳光药业有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
| ES3011607T3 (en) | 2017-09-21 | 2025-04-07 | Chimerix Inc | Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof |
| CA3089498A1 (fr) | 2018-01-26 | 2019-08-01 | Shionogi & Co., Ltd. | Composes cycliques condenses ayant un effet antagoniste du recepteur d3 de la dopamine |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| WO2020055725A1 (fr) | 2018-09-11 | 2020-03-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antagonistes/agonistes partiels sélectifs du récepteur d3 de la dopamine et utilisations associées |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL90279A (en) * | 1988-05-24 | 1995-03-30 | American Home Prod | Piperazinyl carboxamide derivatives, their preparation and pharmaceutical com¦ositions containing them |
| ES2027898A6 (es) * | 1991-01-24 | 1992-06-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina. |
| BR9406128A (pt) * | 1993-03-01 | 1996-02-27 | Merck Sharp & Dohme | Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica |
| HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| KR20050075281A (ko) * | 2002-07-04 | 2005-07-20 | 쉬바르츠파르마에이지 | 씨엔에스 질병의 치료를 위한 도파민-디3 리간드로서헤테로아렌 카복스아미드의 용도 |
| AU2003267201B2 (en) * | 2002-09-14 | 2009-04-23 | The Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Structurally rigid dopamine D3 receptor selective ligands and process for making them |
| JP2004123562A (ja) * | 2002-09-30 | 2004-04-22 | Japan Science & Technology Corp | 神経細胞死抑制作用を有する化合物を用いた医薬 |
| NZ543482A (en) * | 2003-05-21 | 2009-02-28 | Prosidion Ltd | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase |
| SE0401655D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
-
2004
- 2004-11-12 DE DE102004054634A patent/DE102004054634A1/de not_active Ceased
-
2005
- 2005-11-11 WO PCT/EP2005/012127 patent/WO2006050976A1/fr not_active Ceased
- 2005-11-11 CN CNA2005800387992A patent/CN101056878A/zh active Pending
- 2005-11-11 AU AU2005303904A patent/AU2005303904A1/en not_active Abandoned
- 2005-11-11 BR BRPI0517846-0A patent/BRPI0517846A/pt not_active IP Right Cessation
- 2005-11-11 CA CA002575668A patent/CA2575668A1/fr not_active Abandoned
- 2005-11-11 KR KR1020077009695A patent/KR20070083843A/ko not_active Withdrawn
- 2005-11-11 EA EA200700909A patent/EA200700909A1/ru unknown
- 2005-11-11 EP EP05805690A patent/EP1771448A1/fr not_active Withdrawn
- 2005-11-11 MX MX2007005649A patent/MX2007005649A/es not_active Application Discontinuation
- 2005-11-11 US US11/667,601 patent/US20070299091A1/en not_active Abandoned
- 2005-11-11 JP JP2007540597A patent/JP2008519797A/ja active Pending
-
2006
- 2006-12-25 IL IL180317A patent/IL180317A0/en unknown
-
2007
- 2007-01-09 ZA ZA200700252A patent/ZA200700252B/xx unknown
- 2007-05-22 NO NO20072601A patent/NO20072601L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL180317A0 (en) | 2007-06-03 |
| JP2008519797A (ja) | 2008-06-12 |
| KR20070083843A (ko) | 2007-08-24 |
| CN101056878A (zh) | 2007-10-17 |
| ZA200700252B (en) | 2009-05-27 |
| EP1771448A1 (fr) | 2007-04-11 |
| DE102004054634A1 (de) | 2006-05-18 |
| EA200700909A1 (ru) | 2007-12-28 |
| CA2575668A1 (fr) | 2006-05-18 |
| WO2006050976A1 (fr) | 2006-05-18 |
| MX2007005649A (es) | 2007-07-09 |
| US20070299091A1 (en) | 2007-12-27 |
| BRPI0517846A (pt) | 2008-10-21 |
| AU2005303904A1 (en) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072601L (no) | Azaindolkarboksamider | |
| DK2023918T3 (da) | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser | |
| NO20073831L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
| NO20083917L (no) | Malonamidderivater som gammasekretaseinhibitorer | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| NO20083562L (no) | Cannabinoidreseptormodulatorer | |
| NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
| NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
| NO20074615L (no) | Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer | |
| ATE509917T1 (de) | Gamma-secretase-inhibitoren | |
| NO20084328L (no) | Nye forbindelser | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| HUP0301513A2 (hu) | O-Aril-glükozid SGLT2 inhibitorok és eljárás elżállításukra | |
| NO20062704L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
| NO20081942L (no) | Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser | |
| WO2005013892A3 (fr) | Agents therapeutiques contenant du bore et a resistance hydrolytique et procedes pour les utiliser | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| NO20085100L (no) | Nye forbindelser | |
| NO20081804L (no) | Pyrazolforbindelser egnet til behandling av inflammasjon | |
| NO20081888L (no) | Triazolforbindelser som lipoksygenaseinhibitorer | |
| NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
| NO20073830L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |